Clinical Trials
6 results for Bladder Cancer
A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)
- Condition: Bladder Cancer
- Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
- Study ID: NCT03520491
A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
- Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
- Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
- Study ID: NCT03844256
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- Condition: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Study ID: NCT05987241
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
- Condition: Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Study ID: NCT06257017
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients With MIBC (RAD-SG).
- Condition: Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Study ID: NCT05833867
Understanding Tumor and Immune Dynamics and Predicting Response to Various Perioperative Therapies in Patients With Muscle-invasive Bladder Cancer
- Condition: Bladder Cancer
- Study ID: NCT06341478